dose optimization trial

Biotech Stocks with Active Concerns: Genocea Biosciences, Inc. (NASDAQ:GNCA …
www.senecaglobe.com

… cell-directed vaccines and immunotherapies, recently reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of …

3
Like
Save
3 Biotech Stocks Getting Some Love -Genocea Biosciences Inc (NASDAQ:GNCA …
www.wsobserver.com

The company, on October 7, 2015, declaredpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

6
Like
Save
Genocea (GNCA) Stock | Shares Trade Higher on Phase 2 Results
www.warriortradingnews.com

Wednesday they announced positive results from an interim study of data collected over a six month period dosing from its ongoing Phase 2 dose optimization trial evaluating their pipeline drug, GEN-003 for the treatment of genital herpes. When …

2
Like
Save
Premarket Biotech Digest: Evoke Pharma Rallies, Avelumab Fast Tracked, Vertex …
seekingalpha.com

… Phase II Trial of GEN-003 – Genocea Biosciences (NASDAQ:GNCA) announced positive results from a planned interim analysis of data collected six months after dosing from its Phase II dose optimization trial of GEN-003 for the treatment of genital herpes.

2
Like
Save
Checklist Early morning Stocks: SBA Communications Corporation (NASDAQ:SBAC …
www.wsnews4investors.com

Genocea Biosciences, Inc. (GNCA reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

3
Like
Save
Pre-market most advance: Genocea Biosciences (NASDAQ:GNCA), Breitburn Energy …
www.benchmarkmonitor.com

Genocea Biosciences, Inc. (NASDAQ:GNCA) announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

3
Like
Save
Pre-Open Stock Movers 10/07: (GNCA) (SUNE) (GBX) Higher; (AXPW) (ADXS) (YUM …
www.streetinsider.com

… Inc. (NASDAQ: GNCA) 21.9% HIGHER; announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its …

8
Like
Save
Genocea Reports Second Quarter 2015 Financial Results
www.businesswire.com

"We were extremely pleased to report positive top-line results in May from our Phase 2 dose optimization trial of GEN-003, our immunotherapy against genital herpes, which improved upon the already attractive efficacy profile from our prior Phase 1/2a …

7
Like
Save
Morning Buzz: Genocea Biosciences, Inc. (NASDAQ:GNCA), Conatus …
www.stocktranscript.com

On 20 May, Genocea Biosciences, Inc. (NASDAQ:GNCA) announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of …

8
Like
Save
Today's Hot List: Genocea Biosciences, Inc. (NASDAQ:GNCA), Immunomedics …
www.stocktranscript.com

On 20 May, Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of …

2
Like
Save